KẾT QUẢ ĐIỀU TRỊ UNG THƯ THỰC QUẢN GIAI ĐOẠN IV BẰNG PHÁC ĐỒ MFOLFOX6 TẠI BVTWQĐ 108

Abstract

Background: Systemic chemotherapy is the main treatment for patients with esophageal stage IV. In Vietnam, there are very few publications on the effectiveness and safety of the mFOLFOX6 regimen for this group of patients Purpose: To evaluate  effectiveness and safety of the mFOLFOX6 regimen in treatment stage IV esophageal cancer. Subjects, research methods: in this retrospective study, medical records reviewed for 64 patients with stage IV esophageal cancer.was treated with mFOLFOX6 chemotherapy regimen at 108 Military Central Hospital from April 1, 2022 to February 28, 2025. Results: 100% of the study patients were male. The median age was 61.59 ± 7.6. Metastatic recurrence accounted for 35.9%, stage IVB accounted for 85.9%, PS- ECOG  = 1 point accounted 87.5%. The disease control rate was 75,5%. With a mean follow-up time of 12.1 months (from 3 to 33 months), the median overall survival time was 11 months (95%cl: 10.6-11.4), the median progression-free survival was 6,0 tháng (KTC 95%: 5,19–6,81 tháng). Common adverse event were: anemia 20.3% (10.9% grade 3 or higher), leukopenia 37.5% (9.4% grade 3 or higher), neutropenia 35.9% (18.8% grade 3 or higher), thrombocytopenia 48.4% (4.7% grade 3 or higher), sensory neuropathy 20.3% (9.4% grade 3 or higher). No patient deaths related to treatment. Conclusions: Treatment of stage IV esophageal cancer with mFOLFOX6 regimen has good results, and adverse event can be controlled.